CTI BioPharma presents PERSIST-2 data at ASH meeting

CTI BioPharma Corp.'s data from its PERSIST-2 Phase 3 clinical study was presented as a late-breaking oral session at the 58th American Society of Hematology (ASH) Annual Meeting, which was held in San Diego Dec. 3-6.
The Phase 3 PERSIST-2 study compares pacritinib to the best available therapy (BAT) as designated by physicians for the treatment of patients with high risk, thrombocytopenic myelofibrosis.
"Patients with myelofibrosis who have low platelet counts are often intolerant of ruxolitinib therapy and have no effective treatment options," Icahn School of Medicine at Mount Sinai Dr. John Mascarenhas, who presented the data at the ASH meeting, said. "Data from PERSIST-2 suggest that pacritinib dosed on a twice-daily schedule may prove to be effective therapy for thrombocytopenic myelofibrosis patients with an adequate safety profile to fill an important unmet clinical need."
The data that was presented at the ASH meeting will show the positive response rate myelofibrosis patients had in spleen volume reduction when the pacritinib therapy was administered, compared to that of the BAT, which was used in conjucntion with the JAK1/JAK2 inhibitor ruxolitinib.